Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

microRNA-10b antagomir-iron oxide/dextran-based nanoparticle TTX-MC138

A nanoparticle-based formulation containing an antagomir and oligonucleotide targeting microRNA-10b (miR-10b) encapsulated within a nanoparticle consisting of an iron oxide core that is coated with dextran, with potential antineoplastic activity. Upon administration of microRNA-10b antagomir-iron oxide/dextran-based nanoparticle TTX-MC138, the anti-miR-10b moiety targets and binds to miR-10b inside tumor cells. This inhibits miR-10b and kills miR-10b-overexpressing tumor cells. This may inhibit tumor progression and metastasis. miR-10b, a non-coding RNA that is highly expressed in a variety of metastatic tumor cells, plays a key role in tumor cell migration, invasion and metastasis. The dextran coated iron oxide nanoparticles allow for an increased half-life, decreased clearance and increased tumor cell uptake.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-miR-10b nanoparticle TTX-MC138
microRNA-10b inhibitor TTX-MC138
microRNA-10b-targeted nanoparticle-based formulation TTX-MC138
miR-10b antagomir-containing iron oxide-based nanoparticle TTX-MC138
miR-10b inhibitor TTX-MC138
Code name:TTX MC138
TTX-MC138
TTXMC138
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search